Results 251 to 260 of about 279,445 (313)

Association of COPD with adverse outcomes in heart failure patients with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 799-808, April 2025.
Abstract We performed a systematic review and meta‐analysis to detect the impact of chronic obstructive pulmonary disease (COPD) on the prognosis of heart failure patients with preserved ejection fraction (HFpEF). We systematically screened eligible literature from three electronic databases, PubMed, EMBASE and Cochrane Library, up to April 2023.
Shuo Xu, Zhenbang Gu, Wengen Zhu, Shenghui Feng   +3 more
wiley   +1 more source

The Mechanism of Oxidative Stress in Pulmonary Fibrosis and Research Progress. [PDF]

Antioxidants (Basel)
Xu D, Wang Q, Lyu M, Huang C, Yuan X, Chen X, Huang Y.   +6 more
europepmc   +1 more source

Biomarkers of lung congestion and injury in acute heart failure

ESC Heart Failure, Volume 12, Issue 2, Page 781-789, April 2025.
Abstract Acute heart failure (AHF) classification and management are primarily based on lung congestion and/or hypoperfusion. The quantification of the vascular and tissue lung damage is not standard practice though biomarkers of lung injury may play a relevant role in this context.
Marco Guazzi, Gabriele Novello, Francesca Bursi, Anna Caretti, Noemi Furlotti, Ross Arena, Paola Argiento, Julio Núñez, Antoni Bayes‐Genis, Marco Metra   +9 more
wiley   +1 more source

Design of an open-label extension trial of nerandomilast (BI 1015550) in patients with idiopathic pulmonary fibrosis and progressive pulmonary fibrosis (FIBRONEER™-ON). [PDF]

BMC Pulm Med
Wuyts WA, Richeldi L, Assassi S, Azuma A, Cottin V, Hoffmann-Vold AM, Kreuter M, Oldham JM, Martinez FJ, Valenzuela C, Wijsenbeek MS, Kanakapura M, James A, Weimann G, Drzewuski C, Coeck C, Maher TM.   +16 more
europepmc   +1 more source

Salvianolic Acid B Inhibited LH2 Expression to Reduce Collagen Synthesis in Pulmonary Fibrosis. [PDF]

J Cell Mol Med
Shao S, Rao S, Hu S, Zhang Y, Zheng P, Li C, Zhong L, Long Y, Tian X, Tang X, Luo F.   +10 more
europepmc   +1 more source

An aerosolized dual-action autotaxin inhibitor-PPARγ agonist for the treatment of pulmonary fibrosis. [PDF]

Cell Rep Med
Matralis AN, Stylianaki EA, Ladopoulou EM, Kanellopoulou P, Smyrniotis S, Magkrioti C, Papavasileiou KD, Willems S, Rincon Pabon JP, Nastos D, Galaras A, Moro C, Dedos SG, Kaffe E, Hatzis P, Osman-Ponchet H, Merk D, Politis A, Afantitis A, Tseti I, Antoniou KM, Wells AU, Aidinis V.   +22 more
europepmc   +1 more source

The interplay of ferroptosis and oxidative stress in pulmonary fibrosis: from mechanisms to treatment. [PDF]

Front Cell Dev Biol
Yan P, Wang J, Lei Z, Chang H, Shi W, Wang S.   +5 more
europepmc   +1 more source

Epigenetic regulatory mechanisms and translational applications in idiopathic pulmonary fibrosis. [PDF]

Am J Clin Exp Immunol
Jiang M, Wang Q, Lyu Y, Hou X, Zhou X.
europepmc   +1 more source

Identification of a conserved sequence of disease progression in Idiopathic Pulmonary Fibrosis. [PDF]

Am J Respir Crit Care Med
Huang X, Wu P, Guttentag AR, Quintana M, Kropski JA, Blackwell TS, Salisbury ML.   +6 more
europepmc   +1 more source